Saturday 27 December 2014
Type 2 Diabetes

Ramadan app launched to support diabetics

Merck & Co (MSD), a leading pharmaceutical company, has launched a Ramadan app to aid Muslims with type 2 diabetes who choose to fast during Ramadan. The app will offer patients immediate access to the information kit “F


Coffee not linked to chronic illness: study

Coffee drinkers have no more risk of getting illnesses such as heart disease or cancer, and are less likely to develop type 2 diabetes, according to a German study involving more than 40,000 people over nearly a decade.


Onglyza reduces blood sugar levels: study

Pharmaceutical companies Bristol-Myers Squibb and AstraZeneca have announced results from an investigational phase 3b clinical study of use of Onglyza (saxagliptin) in diabetic patients. The study was based on the addition of Onglyza (saxa


Linagliptin 'significantly lowers blood glucose'

Phase III studies of Linagliptin, a compound being investigated by Boehringer Ingelheim as a once-daily oral treatment in type 2 diabetes, showed that the drug significantly lowered blood glucose, a report said. The drug, a dipeptidyl pept

 1 2 3 4 5 >  Last ›

calendarCalendar of Events